5:28 PM
 | 
Apr 17, 2013
 |  BC Extra  |  Clinical News

Alkermes gains on Phase II MDD data

Alkermes plc (NASDAQ:ALKS) gained $4.12 (16%) to $29.72 on Wednesday after reporting that once-daily oral ALKS 5461 as adjunctive treatment met the primary endpoint in a Phase II...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >